Skip to content

Study · Not a test of the peptide alone · 2023

2 results

Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.

BouSaba J, Vosoughi K, Dilmaghani S, Prokop LJ, Camilleri M

Pharmacogenomics31 Mar 2023Cited by 3 (Europe PMC)

PMID36999540 (opens in a new tab)PMCIDPMC10152409 (opens in a new tab)DOI10.2217/pgs-2022-0192 (opens in a new tab)PepBankPUB-36999540
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewOther

    In adults treated with GLP-1 agonists for weight loss, SNVs in CNR1, GLP-1R and TCF7L2 were associated with weight loss in at least one study.

    In plain wordsIn adults on GLP-1 drugs, some gene variants were linked to weight loss in at least one study.

    Peptide
    Liraglutide
    Outcome
    MixedAssociation of SNVs with weight loss on GLP-1 agonists
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s).
    1 context sentence
    Summary · context
    SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewOther

    In the meta-analysis of studies of weight-loss medications, no consistent effect of SNVs on weight loss was identified.

    In plain wordsIn the combined analysis, no gene variant showed a consistent effect on weight loss with these drugs.

    Peptide
    Liraglutide
    Outcome
    No significant changeMeta-analysis of SNV effects on weight loss
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The meta-analysis did not identify any consistent effect of SNVs.
    1 context sentence
    Summary · context
    SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study).

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.